Department of Pharmacology and Toxicology, Faculty of Pharmacy, Birjand University of Medical Sciences, Birjand, Iran; Experimental and Animal Study Center, Birjand University of Medical Sciences, Birjand, Iran.
Natural Products and Medicinal Plants Research Center, North Khorasan University of Medical Sciences, Bojnurd, Iran; Department of Physiology and Pharmacology, Faculty of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran.
Prog Mol Biol Transl Sci. 2024;204:177-218. doi: 10.1016/bs.pmbts.2023.12.010. Epub 2024 Jan 5.
Liposomal drug delivery systems stand as versatile therapeutic platforms for precisely targeting related elements in cancerous tissues owing to their intrinsic passive and acquired active targeting capabilities and exceptional compatibility with physiologic environments. When the capacity of liposomes as nanocarriers is combined with the revolutionary potential of RNA therapies in affecting undruggable targets, the outcome would be promising drug candidates as game-changers in the cancer treatment arena. However, optimizing liposome composition, physicochemical properties, and surface chemistry is paramount to maximizing their pharmacokinetic and pharmacodynamic attributes. This review highlighted the potential of liposomes as nanovehicles for RNA therapeutics through a literature review and looked at the most recent preclinical and clinical advancements in utilizing liposomal RNA therapeutics for cancer management. Notably, the discovery of novel targets, advancements in liposome engineering, and organizing well-planned clinical trials would help uncover the incredible potential of these nanotherapeutics in cancer patients.
脂质体药物递送系统因其内在的被动和获得的主动靶向能力以及与生理环境的出色兼容性，成为精准靶向癌症组织相关元素的多功能治疗平台。当脂质体作为纳米载体的能力与 RNA 疗法在影响不可成药靶点方面的革命性潜力相结合时，其结果将是改变游戏规则的有前途的候选药物，成为癌症治疗领域的佼佼者。然而，优化脂质体的组成、物理化学性质和表面化学性质对于最大限度地提高其药代动力学和药效学特性至关重要。通过文献回顾，本文强调了脂质体作为 RNA 治疗的纳米载体的潜力，并研究了利用脂质体 RNA 治疗癌症管理的最新临床前和临床进展。值得注意的是，新型靶点的发现、脂质体工程的进步以及精心规划的临床试验的组织将有助于揭示这些纳米药物在癌症患者中的巨大潜力。
